An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This observational study will evaluate the glucocorticoid sparing effect after 12 months of treatment with RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 12 months after the initiation of treatment with RoActemra/Actemra from patients who had been on treatment with >5 mg prednisone or equivalent for at least 3 months .
Percentage of patients receiving </= 5 mg/day prednisone (or equivalent) after 12 months of treatment with RoActemra/Actemra [ Time Frame: approximately 29 months ]
Secondary Outcome Measures :
Efficacy: Disease activity score (DAS 28) [ Time Frame: approximately 29 months ]
Co-medications: dosage and treatment schedules [ Time Frame: approximately 29 months ]
Patient reported outcome: European League against Rheumatism - Rheumatoid Arthritis Impact of Disease score (EULAR-RAID)/Health Assessment Questionnaire - Disease Index (HAQ-DI) [ Time Frame: approximately 29 months ]
Safety: Incidence of adverse events [ Time Frame: approximately 29 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Rheumatoid arthritis patients on treatment with RoActemra/Actemra and > 5 mg/day prednisone (or equivalent)
Adult patients, >/= 18 years of age
Patients with rheumatoid arthritis for whom the rheumatologist decided to introduce RoActemra
Patients taking more than 5 mg/day of oral prednisone (or equivalent) for at least 3 months
Participation in a clinical trial in rheumatoid arthritis